IT
Inverna Therapeutics is developing an RNA splicing modulation platform that targets pseudo-exons to enable precise, allele-specific therapeutic interventions with minimal off-target effects. The platform's lead program focuses on Huntington's disease, leveraging a vast database of potential pseudo-exon targets to enhance treatment efficacy.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Inverna Therapeutics is developing an RNA splicing modulation platform that targets pseudo-exons to enable precise, allele-specific therapeutic interventions with minimal off-target effects. The platform's lead program focuses on Huntington's disease, leveraging a vast database of potential pseudo-exon targets to enhance treatment efficacy.